Redwood Bioscience names executive chairman

Tuesday, October 4, 2011 10:53 AM

Redwood Bioscience has named Peter Van Vlasselaer, PhD, executive chairman to Redwood's board of directors.  In this role, Vlasselaer will be actively guiding Redwood on drug and platform development as well as corporate strategy.  

Currently, Vlasselaer is the executive chairman of iPierian, where he was the interim CEO earlier this year.  He previously served as the founding CEO of Arresto Biosciences which was acquired by Gilead Sciences in December 2010.  

"We are very pleased to be able to access Peter's proven abilities in shepherding novel technologies from research into the clinic and driving value for investors," stated David Rabuka, co-founder, president & chief scientific officer.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs